Protective effects of amlexanox against atherosclerosis
氨来呫诺对动脉粥样硬化的保护作用
基本信息
- 批准号:10362773
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdhesionsAdvisory CommitteesAffectAnabolismAnimalsAortaAreaArterial Fatty StreakArteriesAsthmaAtherosclerosisAttenuatedAwardBile Acid Biosynthesis PathwayBile AcidsBloodBlood GlucoseCCL2 geneCardiovascular DiseasesCause of DeathCell AdhesionCell Adhesion MoleculesCell ProliferationCell WallCell physiologyCellsCholesterolCholesterol HomeostasisChronicCollagen FibrilCultured CellsDataDevelopmentDiabetes MellitusDietDiseaseEndothelial CellsEndotheliumEnergy MetabolismEnvironmentExcretory functionExhibitsExtracellular MatrixFacultyFastingFatty acid glycerol estersFunctional disorderGene ExpressionGene ProteinsGenesGoalsHNF4A geneHealthHematopoietic stem cellsHyperglycemiaHypertensionHypertriglyceridemiaInfiltrationInflammationInflammatoryInsulin ResistanceLDL Cholesterol LipoproteinsLesionLinkLiverMatrix MetalloproteinasesMediatingMentorsMetabolic syndromeModernizationMolecularMonocytosisMusMyocardial InfarctionNecrosisNicotinic AcidsObesityOrganismPathway interactionsPatientsPenetrationPharmaceutical PreparationsPhasePhenotypePhosphotransferasesPlant RootsPlasmaPositioning AttributeResearchResourcesRiskRodentRoleSignal PathwaySmooth Muscle MyocytesSocietiesStainsStrokeTBK1 geneTestingTissuesUp-Regulationabsorptionamlexanoxatherogenesisatheroprotectivebasecareercell motilitychemokinecholesterol absorptioncombatcytokineendothelial dysfunctionezetimibegene synthesisglucose metabolismhepatic gluconeogenesishigh riskhypercholesterolemiaimprovedin vivoinhibitor/antagonistinsulin sensitivitykinase inhibitormacrophagemonocytenon-alcoholic fatty liver diseasepreventprofessorprotective effectstem cell functionsystemic inflammatory responsetenure tracktranscription factortranscriptome sequencingwestern dietwound healing
项目摘要
PROJECT SUMMARY/ABSTRACT
Metabolic syndrome, characterized by hypercholesterolemia, hypertriglyceridemia, hypertension,
hyperglycemia and insulin resistance, has become a major health risk in modern society, and are a leading
cause of death. Among current anti-atherosclerosis medications, Statins and Niacins increase blood glucose
and reduce insulin resistance, making them a high risk for patients with diabetes. Ezetimibe and bile acid
sequestrants do not work as well as Statins. Thus, there is a need for new safe and effective drugs to combat
this devastating disease. Our previous studies demonstrated that amlexanox, an inhibitor of IKK and TBK1,
increases insulin sensitivity and improves glucose metabolism. Recent preliminary data have shown that
amlexanox also attenuates diet-induced atherosclerosis in Ldlr-/- mice. Hypercholesterolemia, systemic chronic
inflammation and aortic cells dysfunction are three major causes of atherosclerosis. Our current study has
indicated that amlexanox improves hypercholesterolemia, attenuates monocytosis and prevents aortic cell
dysfunctions. RNA-seq analysis of liver demonstrated that amlexanox increases expression of genes involved
in bile acid synthesis and secretion, which may explain how amlexanox reduces blood cholesterol. Based on
this preliminary data, we hypothesize that amlexanox protects Ldlr-/- mice from Western diet (WD)-induced
atherosclerosis by increasing cholesterol excretion, reducing inflammation and attenuating aortic cell
dysfunction. The goals for this proposal are to thoroughly assess the anti-atherosclerosis effects of amlexanox,
and uncover the underlying mechanisms. Specific Aim 1 will evaluate the effects of amlexanox on cholesterol
metabolism, which include its absorption, excretion and biosynthesis. Specific Aim 2 will identify a transcription
factor that mediates amlexanox-induced expression of bile acid synthesis genes, and investigate how
amlexanox regulates activity of the transcription factor. Specific 3 will assess effects of amlexanox on
proliferation of hematopoietic stem and progenitor cells (HSPCs) and functions of endothelial cells and smooth
muscle cells to explain how amlexanox exerts its effects on monocytosis and aortic cell dysfunction. The
career goal for the applicant is to become a highly competitive candidate for an independent assistant
professor position by gaining additional expertise in the study of cholesterol metabolism and atherosclerosis.
The outstanding research environments and available resources at UCSD, along with the experts serving on
candidate’s advisory committee will provide exemplary support for the applicant to achieve his career goal.
Furthermore, the candidate’s primary mentor has an exceptional record in successful transitioning trainees to
independent assistant professors. With the support of the K99/R00 award, the candidate will be well positioned
to compete for a tenure track faculty position.
项目摘要/摘要
代谢综合征,以高胆固醇血症、高甘油三酯血症、高血压、
高血糖和胰岛素抵抗,已成为现代社会的一大健康风险,并是
死因是。在目前的抗动脉粥样硬化药物中,他汀类药物和烟碱类药物可提高血糖
并降低胰岛素抵抗,使其成为糖尿病患者的高风险因素。依折麦布和胆汁酸
他汀类药物效果不如他汀类药物。因此,需要新的安全有效的药物来对抗。
这种毁灭性的疾病。我们先前的研究表明,IKK和Tbk1的抑制剂氨来昔诺,
增强胰岛素敏感性,改善葡萄糖代谢。最近的初步数据显示,
氨来昔诺还可以减轻饮食诱导的Ldlr-/-小鼠的动脉粥样硬化。高胆固醇血症,全身性慢性
炎症和主动脉细胞功能障碍是动脉粥样硬化的三个主要原因。我们目前的研究已经
表明氨来昔诺可改善高胆固醇血症,减少单核细胞增多症,并防止主动脉细胞
功能障碍。肝脏的rna-seq分析表明氨来昔诺增加了相关基因的表达。
在胆汁酸的合成和分泌方面,这可能解释了氨来昔诺是如何降低血液胆固醇的。基于
根据这些初步数据,我们假设氨来昔诺对西方饮食(WD)诱导的Ldlr-/-小鼠有保护作用
通过增加胆固醇排泄、减少炎症和抑制主动脉细胞来实现动脉粥样硬化
功能障碍。这项提案的目标是彻底评估氨来昔诺的抗动脉粥样硬化作用,
并揭示其潜在的机制。特定目标1将评估氨来昔诺对胆固醇的影响
代谢,包括其吸收、排泄和生物合成。《特定目标2》将确定一项转录
介导氨来昔单抗诱导胆汁酸合成基因表达的因子,并研究如何
氨来昔诺调节转录因子的活性。特效药3将评估氨来昔诺对
造血干/祖细胞的增殖及内皮细胞和血管内皮细胞功能
解释氨来昔诺如何在单核细胞增多和主动脉细胞功能障碍中发挥作用。这个
应聘者的职业目标是成为一名极具竞争力的独立助理候选人
通过在胆固醇代谢和动脉粥样硬化的研究中获得额外的专业知识,获得了教授的职位。
加州大学圣地亚哥分校杰出的研究环境和可用资源,以及在
候选人顾问委员会将为申请者实现其职业目标提供模范支持。
此外,候选人的主要导师在成功将学员过渡到
独立助理教授。在K99/R00奖项的支持下,候选人将处于有利地位
竞争终身教职。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peng Zhao其他文献
Peng Zhao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peng Zhao', 18)}}的其他基金
A novel pathway controls liver injury in NASH
控制 NASH 肝损伤的新途径
- 批准号:
10500991 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
A novel pathway controls liver injury in NASH
控制 NASH 肝损伤的新途径
- 批准号:
10652652 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Protective effects of amlexanox against atherosclerosis
氨来呫诺对动脉粥样硬化的保护作用
- 批准号:
10400158 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
Protective effects of amlexanox against atherosclerosis
氨来呫诺对动脉粥样硬化的保护作用
- 批准号:
10600835 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant














{{item.name}}会员




